136 related articles for article (PubMed ID: 10364647)
21. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
24. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature.
Arrieta JL; Artalejo FR
Age Ageing; 1998 Mar; 27(2):161-79. PubMed ID: 16296676
[TBL] [Abstract][Full Text] [Related]
25. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
26. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
27. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
28. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
29. Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2000; (3):CD000202. PubMed ID: 10908463
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
32. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
Burback D; Molnar FJ; St John P; Man-Son-Hing M
Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
[TBL] [Abstract][Full Text] [Related]
33. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
[TBL] [Abstract][Full Text] [Related]
34. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
Smith F
J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
37. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
38. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
[TBL] [Abstract][Full Text] [Related]
39. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
[TBL] [Abstract][Full Text] [Related]
40. Tacrine: first drug approved for Alzheimer's disease.
Crismon ML
Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]